IOL Chemicals & Pharmaceuticals Ltd Q2 FY2025 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/ea69gw6mktcqto9pdxcvrtr2.pdf

Key Takeaways


Price & Margin Compression

Singh: “This market is very volatile. It is practically getting impossible to talk about what will be happening after one year. That is the main reason why we are not able to meet our guidance.”

Non-Ibuprofen Diversification

Mahajan: “Non-ibu segment, our target is around 50% export collection from non-ibu segment within upcoming 2 to 3 years which is presently around 23 to 24%.”

Competitive Landscape & SI Group Exit

Singh: “Our strength is that we are 100% backward integrated with respect to this. This mitigates all the locational disadvantage.”

Regulatory & Approval Pipeline


Greenfield Expansion & CAPEX


Guidance & Commitments

CommitmentSpecificsTimeline
Non-ibuprofen export shareReach 50% of segment export collection (from ~24% currently)Within 2–3 years
H2 FY25 performanceBetter than H1 FY25H2 FY25
Q3 FY25 performanceNumbers expected to remain more or less same with slight improvementQ3 FY25
Inventory markdownHigher-cost raw material impact should not recurEntering quarter
Growth CAPEX capitalizationSome CAPEX in CWIP to be capitalisedWithin FY25
Greenfield site commercializationNot before regulatory approvals (6–8 quarters typical)FY26 at earliest
2030 volume targetsOn track for internal production volume projections; pricing and raw material volatility cannot be predictedBy 2030

Key Metrics

MetricQ2 FY25
Total stand-alone income₹532 cr, vs ₹552 cr in Q2 FY24 and ₹510 cr in Q1 FY25
EBITDA₹48 cr, vs ₹71 cr in Q2 FY24 and ₹58 cr in Q1 FY25
EBITDA margin9%, vs 12.9% in Q2 FY24 and 11.4% in Q1 FY25
Net profit₹19 cr, vs ₹38 cr in Q2 FY24 and ₹30 cr in Q1 FY25
EBIT margin, chemical segment0.8%
Exports₹140 cr, vs ₹130 cr in Q2 FY24 and ₹150 cr in Q1 FY25
CAPEX₹83 cr, vs ₹41 cr in Q2 FY24 and ₹50.8 cr in Q1 FY25
R&D spend₹5.8 cr, vs ₹4.5 cr in Q2 FY24 and ₹4.7 cr in Q1 FY25
Consolidated cash and bank balance₹157 cr as on 30th September 2024
Ibuprofen global market share30–35%
Ibuprofen capacity utilization75–80%
Metformin and Paracetamol capacity utilization90–95%
Non-ibuprofen export share24% of non-ibu revenue, up from 10% a year ago
Non-ibuprofen export target~50% of non-ibu revenue within 2–3 years
Capital work in progress₹122 cr as on 30th September 2024